Clinical Trials Logo

Clinical Trial Summary

There is a high medical need to improve treatment outcome for high-grade and low-grade glioma since no curative treatment is available. To achieve this goal, a broader understanding is needed of the causes of inter-and intratumoral heterogeneity; glioma dedifferentiation and invasion; the major determinants of malignancy and treatment failure in glioma patients. Patient-derived organoid (PDOs) of high-grade gliomas and low-grade gliomas will be used to identify the mechanisms that underlie this malignant behaviour and treatment resistance. This insight may be used to develop patient avatars to simultaneously test multiple new treatment modalities that are predictive for survival and quality of life of glioma patients.

Clinical Trial Description

To establish primary patient-derived three-dimensional organoid cultures from low grade and high-grade gliomas to study the mechanisms that contribute to i.e. resistance to radiotherapy and/or chemotherapy and immunotherapy, dedifferentiation, tumor invasion among others, in primary and recurrent tumors. Primary Objectives: 1. Establishment of primary patient-derived organoids (PDO) of 'de novo' and recurrent high-grade glioma (HGG) and low-grade glioma (LGG) 2. Phenotypic, genetic, epigenetic and transcriptomic characterization of HGG and LGG organoids and resemblance to the parental tumor (i.e. characterization of specific cell populations and genomic and transcriptomic profiles of PDOs) 3. Investigation of combinations of new or standard glioma systemic treatments (i.e immunotherapy, chemotherapy) with or without radiation (i.e. protons, photons). Secondary objectives 1. Establishment of co-cultures of HGG and LGG organoids with immune cells. 2. Investigation of radiation-triggered cell death mechanisms on PDOs after irradiation with photons and protons. 3. Investigation of dedifferentiation mechanisms of LGG to HGG in the context of radiation w/wo immunotherapy. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04865315
Study type Observational
Source Maastricht Radiation Oncology
Status Active, not recruiting
Start date February 1, 2021
Completion date December 2024

See also
  Status Clinical Trial Phase
Terminated NCT01902771 - Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors Phase 1
Recruiting NCT02655601 - Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 Phase 2
Recruiting NCT01466686 - Low Dose Radiation Therapy for Glioblastoma Multiforme Phase 2
Recruiting NCT03690869 - REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma Phase 1/Phase 2
Recruiting NCT03775369 - Glioma and Exercising N/A
Not yet recruiting NCT04254419 - Intra-tumoral Injection of Natural Killer Cells in High-Grade Gliomas Phase 1
Completed NCT00780819 - Borderzone Sampling N/A
Completed NCT01390948 - A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma Phase 2
Recruiting NCT03952598 - Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy N/A
Active, not recruiting NCT02022644 - Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma Phase 1
Completed NCT01222754 - Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas Phase 1
Active, not recruiting NCT03355794 - A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) Phase 1
Recruiting NCT02885324 - Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children Phase 2
Recruiting NCT02970448 - Expedited Laser Interstitial Thermal Therapy + Chemoradiation For Newly Diagnosed High Grade Gliomas Early Phase 1
Recruiting NCT03334305 - Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas Phase 1
Terminated NCT00826930 - Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma Phase 1
Recruiting NCT04608812 - Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection Phase 1
Recruiting NCT03294434 - Predicting Sites of Tumour Progression in the Invasive Margin of Glioblastomas (PRaM-GBM Study)
Recruiting NCT04559685 - Study of Sonodynamic Therapy in Participants With Recurrent High-Grade Glioma Early Phase 1
Completed NCT01403610 - Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab Phase 2